

3D Control



LAFORMIN GV-1 / GV-2

Glimepiride 1 mg / 2mg + Voglibose 0.2 mg +
Metformin (ER) 500 mg Tablets

LAFORMIN-GV-1/GV-2

Glimepiride 1 mg / 2mg + Voglibose 0.2 mg + Metformin (ER) 500 mg Tablets

Description:

Laformin GV-1 and GV-2 is a Triple drug Combination consists of Glimepiride, Voglibose and Metformin Extended Release for the treatment and management of type-2 diabetes mellitus in adults.

Indication:

LAFORMIN GV-1/GV-2 is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type-2 diabetes who are already treated with a combination of glimepiride and metformin or whose diabetes is not adequately controlled with metformin alone or for those patients who have initially responded to glimepiride alone and require additional glycemic control.

Mechanism of Action:

- **Glimepiride:** The primary mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells.
- **Metformin:** Metformin improves glucose tolerance in patients with type-2 diabetes (NIDDM), lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
- **Voglibose:** Voglibose is an alpha glucosidase inhibitor which reduces intestinal absorption of starch, dextrin, and disaccharides by inhibiting the action of α -glucosidase in the intestinal brush border. Inhibition of this enzyme catalyzes the decomposition of disaccharides into monosaccharides and slows the digestion and absorption of carbohydrates; the post-prandial rise in plasma glucose is blunted in both normal and diabetic subjects resulting in improvement of post prandial hyperglycemia and various disorders caused by hyperglycemia.
- Hence, the combination of glimepiride, metformin Extended-release and Voglibose complements each other and provides better glycemic control in management of type-2 diabetes and probably in the prevention of its associated macrovascular and microvascular complications.

Dosage:

LAFORMIN GV-1/GV-2 should be initiated once daily, and gradually titrated after assessing the therapeutic response.

La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,
S.G. Highway, Ahmedabad-380015, Gujarat, India.
Phone: + 91-79-6616-8998 | Fax: +91-79-6616-8998
E-mail: info@larenon.com | Web: www.larenon.com

I am:	
Call me on:	
Mail me at:	